Iovance Biotherapeutics shares are trading higher after the company announced regulatory, clinical updates for TIL therapy in advanced non-small cell lung cancer.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics has announced regulatory and clinical updates for TIL therapy in advanced non-small cell lung cancer, which has led to a rise in the company's share prices.
July 10, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics' shares are trading higher after the company announced regulatory and clinical updates for its TIL therapy in advanced non-small cell lung cancer.
The announcement of regulatory and clinical updates for Iovance Biotherapeutics' TIL therapy in advanced non-small cell lung cancer has been positively received by the market, leading to a rise in the company's share prices. This indicates increased investor confidence in the company's potential for growth and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100